WilmerHale Advises Thermo Fisher Scientific in €1.6B Eurobond Public Offering

WilmerHale Advises Thermo Fisher Scientific in €1.6B Eurobond Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
A premier corporate governance and disclosure practice providing timely, tailored and practical advice to public company clients based on in-depth experience and insight.
WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Thermo Fisher Scientific Inc., a provider of equipment, software and services for research, manufacturing, analysis, discovery and diagnostics, announced the completion of its public offering of  €1 billion aggregate principal amount of 0.750% Senior Notes due 2024 and €600 million aggregate principal amount of 1.375% Senior Notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively. The offering closed on September 12, 2016.

The WilmerHale team was led by Partner Knute Salhus and included Partners John Sigel, Julie Hogan Rodgers, Tim Silva, Senior Associate Ryan Mitteness, and Associates Tim Hultzman and Seth Davis.

For more information, read Thermo Fisher Scientific's press release.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel